Top Story

Vosaroxin combination demonstrated improved survival in AML

December 20, 2014

SAN FRANCISCO — Farhad Ravandi, MD, professor of medicine in the department of leukemia at The University of Texas MD Anderson Cancer Center, discusses data from the VALOR trial.

In the phase 3 study, combination therapy with vosaroxin (Quinprezo, Sunesis) and cytarabine was associated with longer OS in a cohort of more than 700 patients with acute myeloid leukemia.

New next-generation sequencing test launched for thyroid nodules

December 20, 2014
Interpace Diagnostics, a molecular diagnostics subsidiary of PDI, Inc., has recently launched a new next-generation sequencing test designed to determine the difference…
In the Journals

ST2 levels predicted acute GVHD, mortality after double-unit cord blood transplantation

December 19, 2014
High levels of the biomarker suppressor of tumorigenicity 2 at 28 days post-cord blood transplantation independently predicted acute graft-versus-host disease, according…
In the Journals

Anticoagulant, antiplatelet medications carry rare dermatologic surgery hemorrhage risks

December 19, 2014
Dermatologists and dermatologic surgeons should be aware of the bleeding risks of anticoagulant and antiplatelet drugs used for cardiovascular diseases, according to…
More News Headlines »
Cover Story Publication Exclusive
Although imatinib was the first approved tyrosine kinase inhibitor for CML and is the subject of a larger body of evidence, the second-generation inhibitors are more potent, according to Michael W. Deininger, MD, PhD, professor and chief of the division of hematology and hematologic malignancies at Huntsman Cancer Institute at the University of Utah.

Multiple TKIs for first-line CML treatment ‘a mixed blessing’

HemOnc Today, October 25, 2014
The treatment landscape for most blood cancers has evolved rapidly during the past decade, and chronic myeloid leukemia…
More »
Meeting News Coverage Video
thumbnail for video 3949008667001

Data show encouraging advances in treatment of AML

December 17, 2014
SAN FRANCISCO – According to preliminary data presented at the ASH Annual Meeting and Exposition, FLT3 inhibitors…
More »